Skip to main content

Table 1 Evidence profile

From: Influenza vaccines licensed in the United States in healthy children: a systematic review and network meta-analysis (Protocol)

Quality assessment Number of patients Effect Quality Importance
Number of studies Design Risk of bias Inconsistency Indirectness Imprecision Other considerations LAIV IIV RR (95% CI) Absolute   
Laboratory confirmed influenza (follow-up; assessed with: PCR or viral culture)
  Randomized trials            HIGH CRITICAL
Influenza like illness (follow-up; assessed with)
  Randomized trials            HIGH IMPORTANT
Hospitalization (follow-up; assessed with)
  Randomized trials            HIGH CRITICAL
Medically attended respiratory illness (follow-up; assessed with)
  Randomized trials            HIGH CRITICAL
Fever due to vaccination (follow-up mean, assessed with)
  Randomized trials            HIGH IMPORTANT
Guillain-Barre syndrome (follow-up mean, assessed with)
  Observational study            ΟΟ LOW IMPORTANT
Anaphylaxis (follow-up mean, assessed with)
  Observational study            ΟΟ LOW CRITICAL
  1. Question: Should LAIV versus IIV be used for influenza?
  2. Settings: healthy children.
  3. CI, confidence interval; IIV, inactivated influenza vaccines; LAIV, live-attenuated influenza vaccines; RR; relative risk.